Donald Eagerton, MD
Endocrinology, Diabetes & Metabolism · Myrtle Beach, SCNPI 1609872498
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $231,315 of the $284,291 with a category attached, or 81.4%. 60 manufacturers reported payments, led by Novo Nordisk at 41.0% of the total. Among endocrinology, diabetes & metabolism clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,307 payments — averaging $217.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$116K
- Lilly USA, LLC$67K
- Boehringer Ingelheim$46K
- Sanofi-aventis U.S. LLC$29K
- Merck$10K
- Amgen$4K
- plus $12K from 54 others
Across 4,341 payments — averaging $1752.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$5.3M
- Pfizer$976K
- Eli Lilly$748K
- Novo Nordisk AS$314K
- Boehringer Ingelheim$167K
- Amgen$55K
- plus $47K from 5 others
What the payments were for
- Consulting fees$10,4134%
- Speaking & faculty fees$231,31581%
- Travel & lodging$20,4937%
- Food & beverage$21,7218%
- Education$3480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$103,697
- RYBELSUS$49,212
- Ozempic$44,382
- SOLIQUA 100/33$13,518
- TOUJEO$8,049
- Tresiba$7,446
- STEGLATRO$7,230
- TZIELD$6,323
- Xultophy 100/3.6$4,118
- JANUMET$2,310
- TEPEZZA$1,511
- MINIMED 780G$1,019
- MINIMED 770G$291
- FARXIGA$250
- MOUNJARO$243
- SAPHNELO$234
- LOKELMA$128
- Kerendia$125
- FreeStyle Libre 2$125
- FREESTYLE LIBRE 3$109
How this compares
$284,291 in reported general payments places this provider in the 90th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 22 | $1,215,958 |
| OzempicSemaglutide | 501 | $818,680 |
| JardianceEmpagliflozin | 328 | $412,346 |
| MounjaroTirzepatide | 186 | $270,950 |
| FarxigaDapagliflozin Propanediol | 140 | $180,117 |
| Tresiba Flextouch U-200Insulin Degludec | 117 | $157,512 |
| TrulicityDulaglutide | 86 | $125,988 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $97,717 |
| JanuviaSitagliptin Phosphate | 75 | $97,021 |
| RybelsusSemaglutide | 36 | $64,442 |
| Tresiba Flextouch U-100Insulin Degludec | 83 | $62,798 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 42 | $54,541 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 40 | $49,451 |
| FiaspInsulin Aspart (Niacinamide) | 34 | $48,554 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $48,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $935 | $1,396,074162 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Xultophy 100-3.6, Novolog | $116,474 | $990,667637 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Trijardy Xr | $45,937 | $489,716402 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $66,762 | $415,522326 claims |
| MerckJanuvia, Janumet Xr | $9,946 | $130,175114 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $28,667 | $54,54142 claims |
| Radius Health, Inc.Tymlos | $614 | $36,84314 claims |
| AbbVieSynthroid | $881 | $36,254351 claims |
| Johnson & JohnsonInvokana | $1,045 | $29,94431 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $25 | $6,574442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Myrtle Beach
- Gauri DhirMyrtle Beach$417K
- Anne LarochelleMyrtle Beach$32K
- Jocelyn MyersMyrtle Beach$26K
- Alimitha KodaliMyrtle Beach$5K
- Zhiwei ZhangMyrtle Beach$3K
- Paul BunnMyrtle Beach$3K
- Matthew CrabtreeMyrtle Beach$2K
- Sahana ParthasarathyMyrtle Beach$2K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.